Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 4;17(1):2432462.
doi: 10.1080/20523211.2024.2432462. eCollection 2024.

Long-Term clinical efficacy of liraglutide for type 2 diabetes: real-world evidence and outcomes from Pakistan

Muhammad Daoud Butt  1   2 , Siew Chin Ong  1 , Azra Rafiq  3   4 , Nighat Batool  5 , Rumana Saifi  2   6 , Samina Yaseen  7 , Irum Kaukab  7 , Basit Ramzan  1
Affiliations

Long-Term clinical efficacy of liraglutide for type 2 diabetes: real-world evidence and outcomes from Pakistan

Muhammad Daoud Butt et al. J Pharm Policy Pract. .

Abstract

Background: Liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has demonstrated efficacy in improving glycemic control and promoting weight loss in clinical trials. However, real-world data from diverse populations, particularly from South Asia, are limited. The study aims to evaluate the long-term efficacy and safety of liraglutide in a real-world setting among Pakistani patients with type 2 diabetes mellitus (T2DM).

Methodology: A retrospective cohort study of 624 patients initiated on liraglutide was conducted. Data were collected at baseline and 6, 12, 18, and 24 months. Primary outcomes were HbA1c and weight changes. Secondary outcomes included fasting plasma glucose, lipid profile, and blood pressure. Statistical analyses were performed using appropriate methods.

Results: In study population the mean HbA1c reduction of -1.45 ± 0.67% was observed at 24 months, with 30.6% achieving HbA1c ≤ 7.5%. A rapid and sustained weight loss of -7.51 kg was achieved, with 27.2% experiencing ≥5% weight loss. Additionally, liraglutide led to a significant reduction in LDL cholesterol, with 46.7% of patients achieving a ≥ 10% reduction at 24 months. Liraglutide was well-tolerated, with a low discontinuation rate of 4.6%.

Conclusion: Liraglutide demonstrated sustained efficacy and safety in a diverse Pakistani population with T2DM, regardless of baseline characteristics. These findings support the use of liraglutide as an effective treatment option for T2DM in real-world clinical practice.

Keywords: Glucagon-like peptide (GLP-1); clinical effectiveness; diabetes mellitus type 2; glycemic control; real-world data.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

Figure 1.
Figure 1.
Fraction of doses at different intervals.
Figure 2.
Figure 2.
Patient-reported side effect profiles.
Figure 3.
Figure 3.
Mean change from baseline to 24 months. HbA1c glycated hemoglobin.
Figure 4.
Figure 4.
Mean change from baseline to 24 months. Weight (kg).
See this image and copyright information in PMC

References

    1. Ahrén, B., & Burke, B. (2012). Using albumin to improve the therapeutic properties of diabetes treatments. Diabetes, Obesity and Metabolism, 14(2), 121–129. 10.1111/j.1463-1326.2011.01482.x - DOI - PubMed
    1. Arya, R., Antonisamy, B., & Kumar, S. (2012). Sample size estimation in prevalence studies. The Indian Journal of Pediatrics, 79(11), 1482–1488. 10.1007/s12098-012-0763-3 - DOI - PubMed
    1. Astrup, A., Rössner, S., Van Gaal, L., Rissanen, A., Niskanen, L., Al Hakim, M., … Lean, M. E. (2009). Effects of liraglutide in the treatment of obesity: A randomised, double-blind, placebo-controlled study. The Lancet, 374(9701), 1606–1616. 10.1016/S0140-6736(09)61375-1 - DOI - PubMed
    1. Bensignor, M. O., Kelly, A. S., & Arslanian, S. (2022). Anti-obesity pharmacotherapy for treatment of pediatric type 2 diabetes: Review of the literature and lessons learned from adults. Frontiers in Endocrinology, 13, 1043650. 10.3389/fendo.2022.1043650 - DOI - PMC - PubMed
    1. Berra, C., Manfrini, R., Regazzoli, D., Radaelli, M., Disoteo, O., Sommese, C., … Folli, F. (2020). Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. Pharmacological Research, 160, 105052. 10.1016/j.phrs.2020.105052 - DOI - PubMed

LinkOut - more resources